Company Overview
iSpecimen Inc. operates a specialized marketplace designed to connect medical researchers requiring access to subjects, samples, and data with hospitals and laboratories globally. This business model falls within the Healthcare sector, specifically the Diagnostics & Research industry, positioning the firm as a facilitator for life science innovation rather than a direct manufacturer of pharmaceuticals or medical devices. The company maintains a market capitalization of $1.43M and employs a workforce of 24 individuals to support its proprietary online platform, iSpecimen Marketplace. These financial metrics indicate that the company operates on a micro-cap scale with minimal operational overhead, suggesting a niche market presence where revenue generation is currently constrained by high burn rates and limited market penetration relative to larger established diagnostics firms.
Financial Health
The company reported revenue of $3.35M over the trailing twelve months, yet recorded a net income of -$11,533,098, revealing a severe discrepancy where operating costs and other expenses vastly exceed gross revenue. This structural gap is further highlighted by an EBITDA of -$11,870,482, indicating that even before interest and tax considerations, the core business operations are generating a substantial loss. Additionally, free cash flow stands at -$4,521,631, which signifies a significant outflow of cash that limits the company's financial flexibility and ability to fund operations without external capital injections. The margin profile is equally striking, with a gross margin of 21.6% showing some efficiency in direct costs, but an operating margin of -2655.2% and a profit margin of 0.0% demonstrating that overhead expenses are disproportionately high compared to sales volume. Regarding liquidity, the company holds $2.78M in cash against $281,436 in debt, yet the debt-to-equity ratio of 9.16 suggests a highly leveraged balance sheet structure that exposes the firm to significant financial risk. The current ratio of 0.63 further indicates that current liabilities exceed current assets, pointing to potential challenges in meeting short-term obligations without immediate refinancing or asset liquidation. Finally, the return on equity of -296.2% and return on assets of -74.8% reveal that management is currently destroying value rather than generating returns for shareholders or optimizing asset utilization.
Valuation Assessment
Valuation metrics for iSpecimen Inc. present a complex picture due to the company's negative earnings, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -0.18, implying that traditional earnings-based valuation models are not applicable given the current loss trajectory. The price-to-book ratio is 0.47, which indicates that the market values the company at less than half of its net asset value, suggesting a deep discount to book value rather than a premium. Alternatively, the price-to-sales ratio of 0.43 and an EV/EBITDA of 0.09 offer a different perspective, showing that the market is pricing the stock at a fraction of its sales, a metric often seen in early-stage or distressed companies. In terms of trading range, the stock has a 52-week high of $3.18 and a 52-week low of $0.14, meaning the current price sits significantly below the yearly peak while trading well above the recent floor. The beta of 1.88 indicates that the stock price is highly volatile, moving with much greater intensity than the broader market, which increases the risk profile for traders seeking stability. These metrics collectively suggest a high-risk asset with valuation parameters that diverge sharply from standard blue-chip equities.
Growth & Income
Revenue growth (YoY) has declined by -96.0%, while earnings growth (YoY) is N/A due to the absence of prior year comparable earnings, suggesting that the company has not yet achieved consistent profitability or stable growth patterns. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate for sustainability, as the firm currently reinvests its limited resources into operational expansion rather than distributing cash to shareholders. The combination of negative revenue growth and the lack of a dividend history paints an overall growth and income profile that is characterized by contraction and a reliance on equity financing for survival. Consequently, the company's financial narrative is defined by high volatility and a lack of income generation, requiring investors to focus on potential operational turnaround rather than current cash returns or steady revenue expansion.